[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 77, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 21.81, "open": 21.48, "dayLow": 21.2, "dayHigh": 22.01, "regularMarketPreviousClose": 21.81, "regularMarketOpen": 21.48, "regularMarketDayLow": 21.2, "regularMarketDayHigh": 22.01, "payoutRatio": 0.0, "beta": -0.032, "forwardPE": -11.25926, "volume": 445127, "regularMarketVolume": 445127, "averageVolume": 857890, "averageVolume10days": 807440, "averageDailyVolume10Day": 807440, "bid": 21.17, "ask": 21.4, "bidSize": 1, "askSize": 1, "marketCap": 2389126912, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 50.681522, "fiftyDayAverage": 20.1502, "twoHundredDayAverage": 20.81285, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1581032064, "profitMargins": 0.0, "floatShares": 54899238, "sharesOutstanding": 112271000, "sharesShort": 6878437, "sharesShortPriorMonth": 6970274, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.061300002, "heldPercentInsiders": 0.00386, "heldPercentInstitutions": 1.10509, "shortRatio": 7.07, "shortPercentOfFloat": 0.0731, "impliedSharesOutstanding": 115284000, "bookValue": 6.93, "priceToBook": 3.0707073, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -187358000, "trailingEps": -1.84, "forwardEps": -1.89, "enterpriseToRevenue": 33.539, "enterpriseToEbitda": -8.34, "52WeekChange": 0.33500624, "SandP52WeekChange": 0.20277917, "quoteType": "EQUITY", "currentPrice": 21.28, "targetHighPrice": 52.506664, "targetLowPrice": 26.815071, "targetMeanPrice": 41.712265, "targetMedianPrice": 42.331017, "recommendationMean": 1.46154, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 808476992, "totalCashPerShare": 7.201, "ebitda": -189582000, "totalDebt": 389000, "quickRatio": 19.8, "currentRatio": 19.977, "totalRevenue": 47140000, "debtToEquity": 0.05, "revenuePerShare": 0.465, "returnOnAssets": -0.18146999, "returnOnEquity": -0.31511, "grossProfits": 47140000, "freeCashflow": -98995504, "operatingCashflow": -140430000, "revenueGrowth": 1.126, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -23.14473, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1754086385, "regularMarketTime": 1754078401, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.43007, "regularMarketPrice": 21.28, "longName": "NewAmsterdam Pharma Company N.V.", "shortName": "NewAmsterdam Pharma Company N.V", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "epsTrailingTwelveMonths": -1.84, "epsForward": -1.89, "epsCurrentYear": -1.5885, "priceEpsCurrentYear": -13.396286, "fiftyDayAverageChange": 1.1298008, "fiftyDayAverageChangePercent": 0.05606896, "twoHundredDayAverageChange": 0.46714973, "twoHundredDayAverageChangePercent": 0.022445254, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-07-27", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "postMarketChangePercent": 0.0, "postMarketPrice": 21.28, "postMarketChange": 0.0, "regularMarketChange": -0.529999, "regularMarketDayRange": "21.2 - 22.01", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 857890, "fiftyTwoWeekLowChange": 7.2200003, "fiftyTwoWeekLowChangePercent": 0.5135135, "fiftyTwoWeekRange": "14.06 - 27.29", "fiftyTwoWeekHighChange": -6.01, "fiftyTwoWeekHighChangePercent": -0.2202272, "fiftyTwoWeekChangePercent": 33.500626, "earningsTimestamp": 1746707400, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-08-02"}]